BackAardvark Therapeutics Common Stock Overview
Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics Common Stock Return on Equity

Latest ROE for Aardvark Therapeutics Common Stock: -126.3% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

-126.30%

Return on Equity

-126.30%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Aardvark Therapeutics Common Stock (AARD) FAQ

The latest ROE for AARD is -126.3%. That is below the Healthcare sector average of 9.17%. Investors often review this figure alongside Aardvark Therapeutics Common Stock's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, AARD currently prints -126.3% for ROE, while the sector average sits near 9.17%. That is roughly 1476.8% below the sector mean. Large gaps often invite a closer look at Aardvark Therapeutics Common Stock's growth, margins, and balance sheet.

Return on Equity shows how effectively Aardvark Therapeutics Common Stock converts resources into returns. At -126.3%, AARD may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AARD's ROE (-126.3%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Aardvark Therapeutics Common Stock's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.

Questions & Answers